欣力胶囊抑制Ang-Ⅱ刺激引起的心肌细胞肥大

XinLi Capsule Restrains Cardiomyocytes hypertrophy Induced by Angiotensin Ⅱ

目的欣力胶囊为中德实验室自主开发的治疗心力衰竭的药物。本实验将明确欣力胶囊是否能够抑制AngiotensinⅡ刺激引起的心肌细胞肥大。方法以欣力胶囊灌胃大鼠,7 d后取大鼠血清进行细胞水平的血清药理学实验。AngiotensinⅡ刺激原代培养的心肌细胞,分组为:正常对照、AngiotensinⅡ阳性对照、欣力胶囊对照和欣力胶囊药效观察组,其中药效观察组再按照不同剂量分为六组。培养24 h以后,通过3 h掺入实验、蛋白含量测定和细胞表面积计算三种方法确定心肌细胞肥大状态。结果AngiotensinⅡ刺激以后,细胞[3H]摄入量、蛋白含量和细胞表面积均明显增加 (P<0．01)。欣力胶囊能够显著抑制AngiotensinⅡ引起的心肌细胞肥大(vs．AngiotensinⅡ阳性对照,P<0．01)。结论欣力胶囊能够抑制AngiotensinⅡ刺激引起的心肌细胞肥大,从而抑制心肌重塑发生,可能是欣力胶囊治疗心力衰竭的机制之一。

Objective The main component of XinLi capsule （XL） developed by Sino-German Laboratory has been traditionally used to treat chronic heart failure（CHF） in China for thousands years, thus, we aimed to clarify and affirm whether XL attenuates myocardial hypertrophy. Methods To investigate the effect of XL in vitro, the method of serum pharmacology was introduced. Cultured cells derived by neonatal heart were divided into four groups： （ 1 ） normal cell control, （2） cells stimulated by angiotensin- Ⅱ （ 1 μmol/L）, （3）cells treated with XL, and （4）cells treated with XL and angiotensin-Ⅱ. In forth group, there are six subgroups according to the variety of dosage. Then the degree of cardiac myocytes hypertrophy was detected by [^3 H ] leucine uptake, protein synthesis, and cell surface area. Results Treatment with Ang Ⅱ induced neonatal rat cardiac myocyte hypertrophy, as measured by changes in [^3H ] leucine uptake, and cell surface area （ 190% ± 12% , 320% ± 22% , and 410 ± 36%-fold increases, respectively; P 〈 0.01 ）. Cotreatment with serum from rats treated with XL inhibited the Ang H-induced hypertrophy and showed distinct dose-effect relationship. When the ratio of serum from rats treated with XL in total serum reached 0.8, hypertrophy of cardiac myocytes was restrained completely. The serum from rats treated with XL was no influence on cell growth or hypertrophy （ P 〉 0.05 ）. Conclusion These findings indicated that XinLi Capsule attenuates cardiac myocyte hypertrophy in vitro.